Novartis Pharmaceuticals Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (11)
- 2024 (20)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Sponsor content
548 result(s) found, displaying 131 to 140
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in pre-filled syringe.
-
Prescription medicine registrationActive ingredients: inclisiran.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Crizanlizumab
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MAYZENT siponimod 0.25 mg film coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MAYZENT siponimod 2 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AIMOVIG erenumab 140 mg/mL solution for injection in pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AIMOVIG erenumab 140 mg/mL solution for injection in pre-filled pen.